Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.
Hani Babiker, MD
Advertisement
Articles by Hani Babiker, MD
Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Adjuvant CDK4/6 Inhibitors Gain Ground as Oral SERDs Emerge to Tackle Endocrine Resistance in Early HR+ Breast Cancer
3
Gamgertamig Nets FDA Fast Track Designation in Autoimmune Hemolytic Anemia and Immune Thrombocytopenia
4
Multidisciplinary Surgical Developments Balance Disease Control With Functional Considerations in Brain Cancer
5